Related Experiment Videos
Prevention of low dose streptozotocin induced diabetes by muramyl dipeptide
C Leclerc1, E Deriaud, M P Schutze
1Institut Pasteur, Department of Immunology, Paris, France.
Abstract:
The objective of the present investigation was to evaluate the effect of the synthetic immunomodulator MDP on an experimentally induced diabetes. It has been previously demonstrated that a single high dose of streptozotocin (STZ) induces hyperglycemia by direct destruction of pancreatic beta-cells. MDP had no effect on the diabetes induced by high dose STZ injection. However, MDP partially protected mice against the toxicity of STZ. In contrast to the first model, repeated low dosages of STZ have been shown to induce hyperglycemia due to autoimmune destruction of beta-cells. Large dosages of MDP given before these low dosages of STZ markedly decreased the diabetogenic effect of STZ. It is proposed that this protection is due to the immunosuppressive activity of MDP.
Insights
The synthetic immunomodulator MDP did not affect diabetes induced by high-dose streptozotocin (STZ). However, MDP offered partial protection against STZ toxicity and reduced diabetes in an autoimmune model.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is characterized by hyperglycemia.
- Streptozotocin (STZ) is a chemical agent used to induce experimental diabetes.
- Synthetic immunomodulators like MDP can modulate immune responses.
Purpose of the Study:
- To investigate the effect of the synthetic immunomodulator MDP on experimentally induced diabetes.
- To determine if MDP influences STZ-induced hyperglycemia and toxicity.
Main Methods:
- Experimental induction of diabetes using high-dose and low-dose streptozotocin (STZ) in mice.
- Administration of MDP before STZ to evaluate its protective effects.
- Assessment of hyperglycemia and STZ toxicity.
Main Results:
- MDP had no effect on hyperglycemia induced by a single high dose of STZ.
- MDP partially protected mice against the toxic effects of high-dose STZ.
- MDP significantly decreased the diabetogenic effect of repeated low doses of STZ, suggesting a protective role in autoimmune diabetes models.
Conclusions:
- MDP does not prevent direct beta-cell destruction by high-dose STZ.
- MDP exhibits immunosuppressive activity, offering protection against STZ-induced autoimmune diabetes.
- The findings suggest MDP's potential therapeutic relevance in autoimmune-mediated diabetes.